Arcus Biosciences Dirección
Dirección controles de criterios 2/4
El CEO de Arcus Biosciences' es Terry Rosen , nombrado en May 2015, tiene una permanencia de 8.92 años. compensación anual total es $9.05M, compuesta por 3.9% salario y 96.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.31% de las acciones de la empresa, por valor de $4.42M. La antigüedad media del equipo directivo y de la junta directiva es de 3.7 años y 4.1 años, respectivamente.
Información clave
Terry Rosen
Chief Executive Officer (CEO)
US$10.1m
Compensación total
| Porcentaje del salario del CEO | 6.4% |
| Permanencia del CEO | 9yrs |
| Participación del CEO | 0.3% |
| Permanencia media de la dirección | 3.8yrs |
| Promedio de permanencia en la Junta Directiva | 4.2yrs |
Actualizaciones recientes de la dirección
Recent updates
We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth
Mar 20
What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You
Feb 23Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment
Feb 22Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Dec 18Arcus Biosciences: Showing There Might Be Something To TIGIT After All
Dec 15Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?
Nov 30Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey
Nov 20Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data
Aug 29Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation
Aug 08Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates
Jun 15Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk
May 05Arcus Biosciences GAAP EPS of -$0.90 beats by $0.17
Nov 02Analysts Just Slashed Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Numbers
May 12Arcus Biosciences: Not Much Data Yet, But Gilead Deal Is A Huge Value Add
Jan 07Forecast: Analysts Think Arcus Biosciences, Inc.'s (NYSE:RCUS) Business Prospects Have Improved Drastically
Nov 25Analysts Just Shaved Their Arcus Biosciences, Inc. (NYSE:RCUS) Forecasts Dramatically
Aug 08Need To Know: Analysts Are Much More Bullish On Arcus Biosciences, Inc. (NYSE:RCUS) Revenues
Jun 26Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$10m | US$650k | -US$307m |
| Sep 30 2023 | n/a | n/a | -US$293m |
| Jun 30 2023 | n/a | n/a | -US$287m |
| Mar 31 2023 | n/a | n/a | -US$279m |
| Dec 31 2022 | US$9m | US$350k | -US$267m |
| Sep 30 2022 | n/a | n/a | US$80m |
| Jun 30 2022 | n/a | n/a | US$67m |
| Mar 31 2022 | n/a | n/a | US$58m |
| Dec 31 2021 | US$9m | US$367k | US$53m |
| Sep 30 2021 | n/a | n/a | -US$278m |
| Jun 30 2021 | n/a | n/a | -US$199m |
| Mar 31 2021 | n/a | n/a | -US$168m |
| Dec 31 2020 | US$6m | US$326k | -US$123m |
| Sep 30 2020 | n/a | n/a | -US$88m |
| Jun 30 2020 | n/a | n/a | -US$112m |
| Mar 31 2020 | n/a | n/a | -US$95m |
| Dec 31 2019 | US$2m | US$340k | -US$85m |
| Sep 30 2019 | n/a | n/a | -US$80m |
| Jun 30 2019 | n/a | n/a | -US$69m |
| Mar 31 2019 | n/a | n/a | -US$54m |
| Dec 31 2018 | US$1m | US$295k | -US$50m |
| Sep 30 2018 | n/a | n/a | -US$51m |
| Jun 30 2018 | n/a | n/a | -US$63m |
| Mar 31 2018 | n/a | n/a | -US$59m |
| Dec 31 2017 | US$427k | US$315k | -US$53m |
Compensación vs. Mercado: La compensación total de Terry($USD9.05M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD5.55M).
Compensación vs. Ingresos: La compensación de Terry ha aumentado mientras la empresa no es rentable.
CEO
Terry Rosen (63 yo)
9yrs
Permanencia
US$10,120,945
Compensación
Dr. Terry J. Rosen, Ph D., serves as Director at PACT Pharma, Inc. He co-founded Arcus Biosciences, Inc. in 2015 and has been its Chief Executive Officer since May 2015. Dr. Rosen has been the Chairman of...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 9yrs | US$10.12m | 0.31% $ 4.4m | |
| Co- Founder & President | 9yrs | US$4.75m | 1.56% $ 22.1m | |
| Principal Financial Officer & CFO | 3.8yrs | US$3.59m | 0.017% $ 240.4k | |
| Chief Operating Officer | 3.6yrs | US$4.74m | 0.028% $ 393.3k | |
| Chief Medical Officer | 1.8yrs | US$3.69m | 0.015% $ 215.0k | |
| Co-Founder & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| VP of Finance & Principal Accounting Officer | 1.2yrs | sin datos | 0.0032% $ 46.0k | |
| Chief Scientific Officer | 3.3yrs | sin datos | sin datos | |
| General Counsel & Corporate Secretary | 5.8yrs | US$2.92m | 0.047% $ 667.0k | |
| Vice President of Corporate Communications | no data | sin datos | sin datos | |
| Senior Vice President of Human Resources & Operations | no data | sin datos | sin datos | |
| Chief Commercial Officer | 4.9yrs | sin datos | sin datos |
3.8yrs
Permanencia media
51yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de RCUS se considera experimentado (3.7 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 9.1yrs | US$10.12m | 0.31% $ 4.4m | |
| Co-Founder & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Lead Independent Director | 9yrs | US$503.21k | 0.16% $ 2.3m | |
| Independent Director | 6.7yrs | US$479.08k | 0.16% $ 2.2m | |
| Independent Director | 3.4yrs | US$455.83k | 0.016% $ 219.8k | |
| Chairman of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 4.4yrs | US$455.83k | 0.011% $ 157.1k | |
| Independent Director & Member of Scientific Advisory Board | 4yrs | US$500.83k | 0.047% $ 660.5k | |
| Independent Director & Member of Scientific Advisory Board | 9.3yrs | US$470.83k | 0.026% $ 368.8k | |
| Director | 3.8yrs | sin datos | sin datos | |
| Independent Director | 2.8yrs | US$450.83k | 0.0080% $ 112.5k | |
| Member of Scientific Advisory Board | 3.7yrs | sin datos | sin datos |
4.2yrs
Permanencia media
62.5yo
Promedio de edad
Junta con experiencia: La junta directiva de RCUS se considera experimentada (4.1 años de antigüedad promedio).